Transient Efficacy of Octreotide and Pasireotide (SOM230) Treatment in GIP-dependent Cushing's Syndrome

Abstract

We studied a 55-year old woman presenting with features of Cushing's syndrome associated with metabolic abnormalities including severe hypertension and type 2 diabetes. Urinary free cortisol excretion was within normal limits, but an unusual diurnal cortisol rhythm was observed with low morning and high postprandial levels, associated with the absence of cortisol suppression after dexamethasone, suggesting the possibility of GIP-dependent Cushing's syndrome. The diagnosis was confirmed by further investigations, showing significant plasma cortisol responses after a mixed meal test and after oral, but not intravenous glucose administration, as well as ACTH-independent bilateral macronodular adrenal hyperplasia (AIMAH). An aberrant increase in cortisol was also observed after glucagon and terlipressin injections. The patient was first treated with octreotide 100–250 μg thrice daily for 6 months, then with the new multi-ligand somatostatin analogue (SOM 230) 450–900 μg twice daily for 3 months. Although inducing a significant acute suppression of post-prandial cortisol response, both drugs had no effects on the clinical and metabolic abnormalities associated with Cushing's syndrome and new tests performed at the end of each treatment period confirmed escape of post-meal cortisol suppression to therapy. The patient finally underwent a bilateral adrenalectomy, which markedly improved her medical condition and allowed in vitro confirmation by real time RT-PCR quantification of a high aberrant expression of GIP receptor mRNA in adrenal tissue. This case report illustrates the lack of sustained efficacy of somatostatin analogues on GIP-dependent Cushing's syndrome, independent of their affinity for the different somatostatin receptor subtypes.

Key words

GIP-dependent Cushing's syndrome - octreotide - pasireotide

References

• 1 Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction.  Clin Endocrinol. 2010;  73 1-15
• 2 Lacroix A, N’Diaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.  Endocr Rev. 2001;  22 75-110
• 3 Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, Mahoudeau J. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide.  N Engl J Med. 1992;  327 981-986
• 4 Lacroix A, Bourdeau I. Bilateral adrenal Cushing's syndrome: macronodular adrenal hyperplasia and primary pigmented nodular adrenocortical disease.  Endocrinol Metab Clin North Am. 2005;  34 441-458
• 5 Lacroix A, Mircescu H, Hamet P. Clinical evaluation of the presence of abnormal hormone receptors in adrenal Cushing's syndrome.  Endocrinologist. 1999;  9 9-15
• 6 Lampron A, Bourdeau I, Oble S, Godbout A, Schurch W, Arjane P, Hamet P, Lacroix A. Regulation of aldosterone secretion by several aberrant receptors including for GIP in a patient with an aldosteronoma.  J Clin Endocrinol Metab. 2009;  94 750-756
• 7 Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F, Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism.  Eur J Endocrinol. 2009;  160 443-451
• 8 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR.  Nucleic Acids Res. 2001;  29 e45
• 9 Hsiao HP, Kirschner S, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A, Stratakis CA. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular hyperplasia compared with other adrenocortical tumors.  J Clin Endocrinol Metab. 2009;  94 2930-2937
• 10 De Miguel V, Redal MA, Viale ML, Kahan M, Glerean M, Beskow A, Fainstein Day P. Aberrant expression of glucagon receptors in adrenal glands of a patient with Cushing's syndrome and ATCH-independent macronodular adrenal hyperplasia.  Medicina. 2010;  70 254-256
• 11 Libé R, Coste J, Guignat L, Tissier F, Lefebvre H, Barrande G, Ajzenberg C, Tauveron I, Clauser E, Dousset B, Bertagna X, Bertherat J, Groussin L. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome.  Eur J Endocrinol. 2010;  163 129-138
• 12 Joubert M, Louiset E, Do Rego JL, Contesse V, Kong LC, Benhaim A, Mittre H, Lefebvre H, Reznik Y. for the REHOS Study Group . Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors.  Clin Endocrinol. 2007;  68 692-699
• 13 Lacroix A, Tremblay J, Touyz RM, Deng LY, Lariviere R, Cusson JR, Schiffrin EL, Hamet P. Abnormal adrenal and vascular responses to vasopressin mediated by a V₁-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension.  J Clin Endocrinol Metab. 1997;  82 2414-2422
• 14 Arnaldi G, Gasc JM, de Keyzer Y, Raffin-Sanson ML, Perraudin V, Kuhn JM, Raux-Demay MC, Luton JP, Clauser E, Bertagna X. Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors.  J Clin Endocrinol Metab. 1998;  83 2029-2035
• 15 Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Barrande G, Bertherat J, Vaudry H, Lefebvre H. Expression of serotonin_, receptor and coupling of ectopic receptors to protein kinase a and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome.  J Clin Endocrinol Metab. 2006;  91 4578-4586
• 16 Bruns C, Lewis I, Meno-Tetang G, Weckbecker G. SOM 230: a novel somatostatin peptidomimetic with broad somatropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.  Eur J Endocrinol. 2002;  146 707-716
• 17 Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Schmid KW, Mann K, Petersenn S. Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4 and 5 in various adrenal tumors.  Endocr Res. 2004;  30 931-934

Correspondence